Listing of Claims:

1-49. (**Cancelled**)

50. (**Previously presented**) A therapeutic composition for ingestion for the treatment or prophylaxis of a cancerous condition which causes an acidic microenvironment, said composition comprising a proton pump inhibitor and an antacid.

51. (**Previously presented**) A method for treatment or prophylaxis of a cancerous condition which causes an acidic microenvironment, said method comprising the step of oral administration of a therapeutic composition comprising a proton pump inhibitor to a patient in need thereof.

52. (**Previously presented**) The method of claim 51, wherein the cancerous condition is a tumor.

53. (**Previously presented)** The method of claim 52, wherein the tumor is metastatic.

54. (**Previously presented**) The method of claim 51, wherein the proton pump inhibitor is a 2-pyridyl methylsulphinyl benzimidazole proton pump inhibitor.

55. (**Previously presented**) The method of claim 54, wherein the proton pump inhibitor is selected from of omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole, and mixtures thereof.

56. (**Previously presented**) The method of claim 51, further comprising the step of administering to the patient an antacid or an antacid drug in an amount sufficient to prevent total sequestration of the proton pump inhibitor in the stomach of the patient.

57. (**Previously presented**) The method of claim 56, wherein the antacid or

antacid drug is administered prior to the proton pump inhibitor.

58. (**Previously presented**) The method of claim 57, wherein the antacid is calcium carbonate.

59. (**Previously presented**) The method of claim 56, wherein the antacid drug is an H_2-receptor antagonist.

60. (**Previously presented**) The method of claim 59, wherein H_2-receptor antagonist is ranitidine or cimetidine.

61. (**Previously presented**) A method for combination therapy or prophylaxis of a disease condition which causes an acidic microenvironment, wherein said condition is not a gastric condition, said method comprising the steps of:

(a) administering to a patient in need thereof a first therapeutic composition comprising a proton pump inhibitor; and

(b) after step (a), administering to the patient a second therapeutic composition comprising at least one further drug for treating said disease.

62. (**Previously presented**) The method of claim 61, wherein the administering of the first therapeutic composition is sufficiently prior to the administration of the second therapeutic composition so as to reduce the acidity associated with the site of the said condition.

63. (**Previously presented**) The method of claim 62, wherein the administering of the first therapeutic composition of step (a) is between 30 minutes and 3 days prior to administering of the second therapeutic composition of step (b).

64. (**Previously presented**) The method of claim 61, wherein the at least one further drug is selected from the group consisting of vinka alkaloids, taxanes, anthracyclines, anthracenes, epipodophyllotoxins, camptothecins, heavy metal

oxyanions, actinomycin d, mitomycin c, methotrexate, trimetrexate, amsacrine, imitinib, melphalan, 5-fluorouracil and cisplatin.

65. (**Previously presented**) The method of claim 61, wherein the disease condition is resistant to the further drug, and the step of administering the first therapeutic composition comprising the proton pump inhibitor is carried out at a time when levels of the further drug are clinically sub-effective.

66. (**Previously presented**) The method of claim 65, wherein the disease condition is a cancerous condition.

67. (**Previously presented**) The method of claim 66, wherein the condition is a tumor.

68. (**Previously presented**) The method of claim 67, wherein the tumor is metastatic.

69. (**Previously presented**) The method of claim 65, wherein the disease condition is AIDS, rheumatoid arthritis, ulcerative colitis, Crohn's disease, or a combination thereof.

70. (**Previously presented**) The method of claim 69, wherein the condition is AIDS, and the further drug is a highly active antiretroviral therapy (HAART) drug.

71. (**Previously presented**) The method of claim 65, wherein the proton pump inhibitor is a 2-pyridyl methylsulphinyl benzimidazole proton pump inhibitor.

72. (**Previously presented**) The method of claim 71, wherein the proton pump inhibitor is omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole or mixtures thereof.

73. (**Previously presented**) The method of claim 65, wherein the first therapeutic composition further comprises an antacid.

74. (**Previously presented**) The method of claim 72, wherein the proton pump inhibitor is omeprazole.

75. (**Previously presented**) The method of claim 61, wherein the proton pump inhibitor is omeprazole.

76. (**Previously presented**) The therapeutic composition of claim 50, wherein the medicament further comprises an anticancer therapeutic agent.